Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma

Journal of Surgical Oncology

Volumn 100, Issue 7, 2009, Pages 546-552

  Ren, Dan Ni ^a   Kim, Ik Yong ^a   Koh, Sang Baek ^a   Chang, Sei Jin ^a   Eom, Minseob ^a   Yi, Sang Yeop ^b   Seong, Seung Hoon ^a   Kim, Mi Dong ^a   Bronner, Mary P ^c   Cho, Mee Yon ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal adenocarcinoma; Genetic polymorphism; Genotype; Immunohistochemistry; Real time polymerase chain reaction; Reverse transcriptase; Thymidylate synthase

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM REPEAT; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 71549156229     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21383     Document Type: Article

References (30)

1. Ramsoekh D, van Leerdam ME, van Ballegooijen M, et al.: Population screening for colorectal cancer: Faeces, endoscopes or X-rays? Cell Oncol 2007;29:185-194.
2. Wils J: Adjuvant treatment of colon cancer: Past, present and future. J Chemother 2007;19:115-122. (Pubitemid 46697729)
3. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
4. Bertino JR, Banerjee D: Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin Cancer Res 2003;9:1235-1239.
5. Costi MP, Ferrari S, Venturelli A, et al.: Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 2005;12:2241-2258. (Pubitemid 41179710)
6. Edler D, Glimelius B, Hallstrom M, et al.: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728. (Pubitemid 34273259)
7. Fujii R, Seshimo A, Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003;8:72-78. (Pubitemid 36548474)
8. Inoue T, Hibi K, Nakayama G, et al.: Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer. J Gastroenterol 2005;40:143-147. (Pubitemid 40425201)
9. Jensen SA, Vainer B, Sorensen JB: The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2007;120:694-701. (Pubitemid 44969043)
10. Longley DB, McDermott U, Johnston PG: Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J 2002;2:209-216. (Pubitemid 35023580)
11. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22:529-536. (Pubitemid 41079782)
12. Formentini A, Henne-Bruns D, Kornmann M: Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: A review. Langenbecks Arch Surg 2004;389:405-413. (Pubitemid 39517784)
13. Roberts D: An isotopic assay for thymidylate synthetase. Biochemistry 1966;5:3546-3548.
14. Aschele C, Lonardi S, Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28:27-47. (Pubitemid 34679207)
15. Kornmann M, SchwabeW, Sander S, et al.: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124. (Pubitemid 37204028)
16. Chu E, Koeller DM, Casey JL, et al.: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991;88:8977-8981. (Pubitemid 21915553)
17. Morganti M, Ciantelli M, Giglioni B, et al.: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005; 41:2176-2183. (Pubitemid 41337961)
18. Hitre E, Budai B, Adleff V, et al.: Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723-730. (Pubitemid 41345324)
19. Jakobsen A, Nielsen JN, Gyldenkerne N, et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365-1369. (Pubitemid 46260023)
20. Lindebjerg J, Nielsen JN, Hoeffding LD, et al.: Expression of thymidylate synthase in primary colorectal adenocarcinoma. Appl Immunohistochem Molecul Morphol 2006;14:37-41.
21. Mandola MV, Stoehlmacher J, Zhang W, et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14:319-327. (Pubitemid 38638919)
22. Matsui T, Omura K, Kawakami K, et al.: Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol Rep 2006;16:1111-1115.
23. Ulrich CM, Bigler J, Velicer CM, et al.: Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9:1381-1385. (Pubitemid 32044809)
24. Gosens MJ, Moerland E, Lemmens VP, et al.: Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008;123:1941-1949.
25. Greene FL, AJCoC, American Cancer Society: AJCC cancer staging manual. New York: Springer-Verlag; 2002.
26. Min B, Hong J, Lee K, et al.: Significance of thymidylate synthase expression in colorectal cancer. J Korean Surg Soc 2002; 62:408-414.
27. Zimovjanova M, Sykora V, Novotny J, et al.: Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue. Neoplasma 2005;52: 208-210. (Pubitemid 40776431)
28. Etienne MC, Chazal M, Laurent-Puig P, et al.: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J Clin Oncol 2002;20: 2832-2843. (Pubitemid 34651512)
29. Marsh S, Collie-Duguid ES, Li T, et al.: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999;58:310-312. (Pubitemid 29300314)
30. Gosens MJ, Moerland E, Lemmens VP, et al.: Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008;123:1941-1949.